Shelley Hall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shelley Hall has a total of 347 co-authors. Here are the top co-authors by number of shared publications:
- Jon A. Kobashigawa
Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, United States
6 shared publications - Johanna S. van Zyl
Texas A&M University Health Science Center College of Medicine Dallas Texas USA
5 shared publications - Joost Felius
Baylor Scott & White Research Institute, Advanced Heart Failure and Transplant, Baylor University Medical Center, Dallas, Texas
5 shared publications - Kiran K. Khush
Stanford University
5 shared publications - Maryjane Farr
Division of Cardiology, Department of Medicine; Division of Cardiology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
5 shared publications - David A. Baran
Cleveland Clinic Florida, Weston, Florida, USA
4 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
Donor-Recipient Sex Mismatch is Associated with Severe Primary Graft Dysfunction after Heart Transplantation
- 26 October 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
Open AccessDonor-Recipient Sex Mismatch is Associated with Severe Primary Graft Dysfunction after Heart Transplantation
- 8 September 2026
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 32 (9) , 1637-1639
Centralized Care in Heart Transplantation: A Tradeoff Between the Gift of Life and the Burden of Travel
- 8 September 2026
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 32 (9) , 1637-1639
Centralized Care in Heart Transplantation: A Tradeoff Between the Gift of Life and the Burden of Travel
- Open Access
- 1 June 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (6) , e013877
Changes in Pulmonary Artery Pressure Following Initiation of Guideline-Directed Medical Therapies in Patients With Heart Failure: Insights From GUIDE-HF
BACKGROUND: While clinical benefits of guideline-directed medical therapy in patients with heart failure (HF) are well established, acute hemodynamic changes after initiation of these agents are not well described. Wireless pulmonary artery pressure (PAP) monitoring using implantable sensors is ideally suited to determine changes in pressure following medication titration. METHODS: We compared PAP from 7 days pre-initiation to the 7-day period following 30 days of newly initiated treatment with core HF therapies: angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, sodium-glucose co-transporter-2 inhibitors, and β-blockers in patients implanted with a PAP sensor (CardioMEMS, Abbott) as part of the GUIDE-HF study (Hemodynamic-Guided Management of HF). Patients with changes in loop diuretics or other core HF therapies during the 30-day interval were excluded from the analysis. RESULTS: Of 2358 patients in the study, 50 patients had new angiotensin receptor-neprilysin inhibitor initiation, 97 patients had new sodium-glucose co-transporter-2 inhibitor initiation, 112 patients had new mineralocorticoid receptor antagonist initiation, and 33 had new β-blocker initiation at least 30 days post-implant, continued to take the medication for at least 30 days, and were included in this analysis. Following angiotensin receptor-neprilysin inhibitor or mineralocorticoid receptor antagonist initiation, diastolic PAP decreased by −1.56 (95% CI, −3.54 to −0.40) and −1.15 (95% CI, −1.82 to −0.47) mm Hg, respectively, in the absence of changes in loop diuretics or other core HF therapies. By contrast, there was no detectable change in PAP following the new initiation of the sodium-glucose co-transporter-2 inhibitor. A trend to higher PAP was observed after β-blocker initiation though differences were not significant. CONCLUSIONS: These results may inform the selection of pharmacological therapy to manage elevated filling pressures during hemodynamic-guided therapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03387813.
- 1 June 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (6) , e013877
Open AccessChanges in Pulmonary Artery Pressure Following Initiation of Guideline-Directed Medical Therapies in Patients With Heart Failure: Insights From GUIDE-HF
BACKGROUND: While clinical benefits of guideline-directed medical therapy in patients with heart failure (HF) are well established, acute hemodynamic changes after initiation of these agents are not well described. Wireless pulmonary artery pressure (PAP) monitoring using implantable sensors is ideally suited to determine changes in pressure following medication titration. METHODS: We compared PAP from 7 days pre-initiation to the 7-day period following 30 days of newly initiated treatment with core HF therapies: angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, sodium-glucose co-transporter-2 inhibitors, and β-blockers in patients implanted with a PAP sensor (CardioMEMS, Abbott) as part of the GUIDE-HF study (Hemodynamic-Guided Management of HF). Patients with changes in loop diuretics or other core HF therapies during the 30-day interval were excluded from the analysis. RESULTS: Of 2358 patients in the study, 50 patients had new angiotensin receptor-neprilysin inhibitor initiation, 97 patients had new sodium-glucose co-transporter-2 inhibitor initiation, 112 patients had new mineralocorticoid receptor antagonist initiation, and 33 had new β-blocker initiation at least 30 days post-implant, continued to take the medication for at least 30 days, and were included in this analysis. Following angiotensin receptor-neprilysin inhibitor or mineralocorticoid receptor antagonist initiation, diastolic PAP decreased by −1.56 (95% CI, −3.54 to −0.40) and −1.15 (95% CI, −1.82 to −0.47) mm Hg, respectively, in the absence of changes in loop diuretics or other core HF therapies. By contrast, there was no detectable change in PAP following the new initiation of the sodium-glucose co-transporter-2 inhibitor. A trend to higher PAP was observed after β-blocker initiation though differences were not significant. CONCLUSIONS: These results may inform the selection of pharmacological therapy to manage elevated filling pressures during hemodynamic-guided therapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03387813.
- Open Access
- 24 November 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (3) , 388-400
Multimodal molecular testing provides prognostic value for heart transplant recipients
- 24 November 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (3) , 388-400
Open AccessMultimodal molecular testing provides prognostic value for heart transplant recipients
- 11 November 2025
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 31 (11) , 1644-1647
Can Complicated Be Made Simple? A Continuous Distribution Dilemma
- 11 November 2025
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 31 (11) , 1644-1647
Can Complicated Be Made Simple? A Continuous Distribution Dilemma
- Open Access
- 13 May 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (8) , 1601-1613
Recommendations to overcome barriers to transplant fellowship training: A report from the American Society of Transplantation Fellows Task Force
- 13 May 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (8) , 1601-1613
Open AccessRecommendations to overcome barriers to transplant fellowship training: A report from the American Society of Transplantation Fellows Task Force
- 1 November 2024
- Published by Elsevier in The American Journal of Cardiology
- Vol. 235, 30-36
Tailored Therapy in Cardiogenic Shock: Case-Based Management Choices
- 1 November 2024
- Published by Elsevier in The American Journal of Cardiology
- Vol. 235, 30-36
Tailored Therapy in Cardiogenic Shock: Case-Based Management Choices
- Open Access
- 26 March 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (8) , 1414-1426
Redefining the molecular rejection states in 3230 heart transplant biopsies: Relationships to parenchymal injury and graft survival
- 26 March 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (8) , 1414-1426
Open AccessRedefining the molecular rejection states in 3230 heart transplant biopsies: Relationships to parenchymal injury and graft survival
- 13 March 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (3) , e15287
The impact of active cytomegalovirus infection on donor‐derived cell‐free DNA testing in heart transplant recipients
Background: Little is known about the relationship between cytomegalovirus (CMV) infections and donor‐derived cell‐free DNA (dd‐cfDNA) in heart transplant recipients.Methods: In our study, CMV and dd‐cfDNA results were prospectively collected on single‐organ heart transplant recipients. If the CMV study was positive, a CMV study with dd‐cfDNA was repeated 1‐3 months later. The primary aim was to compare dd‐cfDNA between patients with positive and negative CMV results.Results: Of 44 patients enrolled between August 2022 and April 2023, 12 tested positive for CMV infections, 25 were included as controls, and seven patients with a viral infection without CMV were excluded. Baseline characteristics did not differ significantly between CMV‐positive and CMV‐negative patients with the exception of a later median time post‐transplant in the CMV‐positive group (253 days vs. 120 days, p = .03). Dd‐cfDNA levels were significantly higher in patients with CMV infections compared to those without (p < .001) with more patients in the CMV positive group showing dd‐cfDNA results ≥.12% (75% vs. 8%, p < .001) and ≥.20% (58% vs. 8%, p = .002). Each 1 log10 copy/ml reduction in CMV viral load from visit 1 to visit 2 was associated with a.23% reduction in log10 dd‐cfDNA (p = .002).Conclusion: Our findings suggest that active CMV infections may raise dd‐cfDNA levels in patients following heart transplantation. Larger studies are needed to validate these preliminary findings.
- 13 March 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (3) , e15287
The impact of active cytomegalovirus infection on donor‐derived cell‐free DNA testing in heart transplant recipients
Background: Little is known about the relationship between cytomegalovirus (CMV) infections and donor‐derived cell‐free DNA (dd‐cfDNA) in heart transplant recipients.Methods: In our study, CMV and dd‐cfDNA results were prospectively collected on single‐organ heart transplant recipients. If the CMV study was positive, a CMV study with dd‐cfDNA was repeated 1‐3 months later. The primary aim was to compare dd‐cfDNA between patients with positive and negative CMV results.Results: Of 44 patients enrolled between August 2022 and April 2023, 12 tested positive for CMV infections, 25 were included as controls, and seven patients with a viral infection without CMV were excluded. Baseline characteristics did not differ significantly between CMV‐positive and CMV‐negative patients with the exception of a later median time post‐transplant in the CMV‐positive group (253 days vs. 120 days, p = .03). Dd‐cfDNA levels were significantly higher in patients with CMV infections compared to those without (p < .001) with more patients in the CMV positive group showing dd‐cfDNA results ≥.12% (75% vs. 8%, p < .001) and ≥.20% (58% vs. 8%, p = .002). Each 1 log10 copy/ml reduction in CMV viral load from visit 1 to visit 2 was associated with a.23% reduction in log10 dd‐cfDNA (p = .002).Conclusion: Our findings suggest that active CMV infections may raise dd‐cfDNA levels in patients following heart transplantation. Larger studies are needed to validate these preliminary findings.
- Open Access
Association of Hemo-Metabolic Trajectory and Cardiogenic Shock Mortality: Analysis from the CSWG Registry
Background: Cardiogenic shock (CS) is as a hemodynamic disorder that can progress to systemic metabolic derangements. Prior studies have reported hemodynamic parameters associated with mortality in limited cohorts or at single time points. Hemodynamic trajectories have not been described. Objectives: We studied the association between hemodynamics and in-hospital mortality in patients with CS due to heart failure (HF-CS) and acute myocardial infarction (AMI-CS). Methods: Using data from the large multicenter Cardiogenic Shock Working Group (CSWG) registry, we analyzed hemo-metabolic data obtained at the time of pulmonary artery catheter (PAC) insertion (baseline) and at PAC removal or death (final). Univariable regression analyses for prediction of in-hospital mortality were conducted for baseline and final hemo-metabolic values, as well as the interval change (delta-P), and analyzed based on CS etiology and survival status. Results: 2,260 patients with PAC data were included (70% male, age 61±14, 61% HF-CS, 27% AMI-CS). In-hospital mortality was higher in the AMI-CS group (40.1%) compared to HF-CS (22.4%), pHF-CS cohort, survivors exhibited lower right atrial pressure (RAP), pulmonary artery pressures (PAP), cardiac output/index (CO/CI), lactate and higher blood pressure (BP) than non-survivors at baseline. In this cohort, during hospitalization, improvement in metabolic (AST, lactate), BP, hemodynamic (RAP, PAPi, PA compliance for right sided profile and CO/CI for left sided profile), had association with survival. In the AMI-CS cohort, a lower systolic BP and higher PAP were associated with odds of death at baseline. Improvement in metabolic (lactate), BP, hemodynamic (RAP, PAPi for right-sided profile and CO/CI for left-sided profile) were associated with survival. Conclusions: In a large contemporary CS registry, few hemo-metabolics at baseline determined survival in AMI-CS; rather hemodynamic trajectories had a strong association with outcomes in both cohorts. These findings suggest the importance of monitoring hemo-metabolic trajectories to tailor management in patients with CS. What is New?: While previous cardiogenic shock studies have reported hemodynamic parameters associated with mortality in limited cohorts or at single time points, we used data from a large multi-center registry to analyze hemodynamic trajectory in patients with cardiogenic shock from pulmonary artery catheter insertion to removal. We found that few baseline hemodynamic parameters were predictive of survival in AMI-CS. However, in both AMI-CS and HF-CS, the hemodynamic trajectory was strongly associated with outcomes. What Are the Clinical Implications?: Our findings suggest that targeted interventions in patients with cardiogenic shock impact clinical outcomes independently of baseline hemodynamic derangement and highlight the importance of invasive hemodynamic monitoring to tailor management in these patients.
Open AccessAssociation of Hemo-Metabolic Trajectory and Cardiogenic Shock Mortality: Analysis from the CSWG Registry
Background: Cardiogenic shock (CS) is as a hemodynamic disorder that can progress to systemic metabolic derangements. Prior studies have reported hemodynamic parameters associated with mortality in limited cohorts or at single time points. Hemodynamic trajectories have not been described. Objectives: We studied the association between hemodynamics and in-hospital mortality in patients with CS due to heart failure (HF-CS) and acute myocardial infarction (AMI-CS). Methods: Using data from the large multicenter Cardiogenic Shock Working Group (CSWG) registry, we analyzed hemo-metabolic data obtained at the time of pulmonary artery catheter (PAC) insertion (baseline) and at PAC removal or death (final). Univariable regression analyses for prediction of in-hospital mortality were conducted for baseline and final hemo-metabolic values, as well as the interval change (delta-P), and analyzed based on CS etiology and survival status. Results: 2,260 patients with PAC data were included (70% male, age 61±14, 61% HF-CS, 27% AMI-CS). In-hospital mortality was higher in the AMI-CS group (40.1%) compared to HF-CS (22.4%), pHF-CS cohort, survivors exhibited lower right atrial pressure (RAP), pulmonary artery pressures (PAP), cardiac output/index (CO/CI), lactate and higher blood pressure (BP) than non-survivors at baseline. In this cohort, during hospitalization, improvement in metabolic (AST, lactate), BP, hemodynamic (RAP, PAPi, PA compliance for right sided profile and CO/CI for left sided profile), had association with survival. In the AMI-CS cohort, a lower systolic BP and higher PAP were associated with odds of death at baseline. Improvement in metabolic (lactate), BP, hemodynamic (RAP, PAPi for right-sided profile and CO/CI for left-sided profile) were associated with survival. Conclusions: In a large contemporary CS registry, few hemo-metabolics at baseline determined survival in AMI-CS; rather hemodynamic trajectories had a strong association with outcomes in both cohorts. These findings suggest the importance of monitoring hemo-metabolic trajectories to tailor management in patients with CS. What is New?: While previous cardiogenic shock studies have reported hemodynamic parameters associated with mortality in limited cohorts or at single time points, we used data from a large multi-center registry to analyze hemodynamic trajectory in patients with cardiogenic shock from pulmonary artery catheter insertion to removal. We found that few baseline hemodynamic parameters were predictive of survival in AMI-CS. However, in both AMI-CS and HF-CS, the hemodynamic trajectory was strongly associated with outcomes. What Are the Clinical Implications?: Our findings suggest that targeted interventions in patients with cardiogenic shock impact clinical outcomes independently of baseline hemodynamic derangement and highlight the importance of invasive hemodynamic monitoring to tailor management in these patients.